Miao Zhou | Precision Medicine | Best Researcher Award

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome